Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company’s performance and future prospects.
Recent Posts
- J. Kumar Infraprojects Shares Declines 2%; Reports Steady FY26 Performance as Order Book Swells to ₹18,554 Cr
- Hindalco Q4: Breaking Down its Revenue From North America, South America, Europe, and Asia
- Dynamatic Technologies Shares Plummet 7% As Company Reports 25% Decline in Q4 PAT; Board Approves ₹5 Dividend
- Share India Securities Shares In Spotlight After Q4 Profit Jumps 369% YoY; Announces 25% Final Dividend
- Smallcap Stock Skyrockets 15% After Reporting 306% YoY Growth in Net Profit